Onyx's Patent Agent Privilege Claim Fails In Cancer Drug Row
Onyx Therapeutics Inc., which is locked in a dispute with generic-drug makers over the cancer treatment Kyprolis, must turn over certain emails and communications related to drug research, after a Delaware...To view the full article, register now.
Already a subscriber? Click here to view full article